Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peginterferon Alfa-2b Combined With Tenofovir Alafenamide Improves the Functional Cure Rate in Patients With HBeAg Negative Chronic Hepatitis B: an Open-labeled, Multicenter, Randomized and Controlled Clinical Study

NCT05490836 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT05490836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05490836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peginterferon Alfa-2b Combined With Tenofovir Alafenamide Improves the Functional Cure Rate in Patients With HBeAg Negative Chronic Hepatitis B: an Open-labeled, Multicenter, Randomized and Controlled Clinical Study
Lead sponsor
Huashan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2022
Completion date
December 31, 2024
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b